sellWeak
Francisco Leon sold $1.9M of PRVB
Chief Scientific Officer at Provention Bio, Inc.. 187,000 shares at an average of $10.26, traded Dec 29, 2022, filed Dec 30, 2022.
Warning score
30Value
$1.9M
187,000 shares
Holdings after
1,573,000
-11% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$1.9M at market
- +5Share of holdings soldSold 11% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001493152-22-037133, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 29, 2022 | MOption exercise Common Stock | +187,000 | $2.50 | $468k | 1,760,000 | Dec 30, 2022 |
| Dec 29, 2022 | SOpen-market sale Common Stock | -187,000 | $10.26 | $1.9M | 1,573,000 | Dec 30, 2022 |
| Dec 29, 2022 | MOption exercise Stock Option (right to buy)derivative | -187,000 | $0.00 | $0 | 342,103 | Dec 30, 2022 |
Related signals
Other insiders at Provention Bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 42Moderate | PRVBsell Provention Bio, Inc. | Sessa Capital (Master), L.P. owner | $53M 2,190,549 shares | -12% | |
| 36Weak | Provention Bio, Inc. | Jason Hoitt Chief Commercial Officer | $45k 4,500 shares | -100% | |
| 17Weak | Provention Bio, Inc. | Francisco Leon Chief Scientific Officer | $767k 75,985 shares | -5% | |
| 27Weak | Provention Bio, Inc. | Ashleigh Palmer Director and CEO | $765k 75,835 shares | -3% | |
| 8Weak | Provention Bio, Inc. | Francisco Leon Chief Scientific Officer | $247k 24,015 shares | -2% | |
| 18Weak | Provention Bio, Inc. | Ashleigh Palmer Director and CEO | $248k 24,165 shares | -1% | |
| 57Moderate | Provention Bio, Inc. | Sessa Capital (Master), L.P. owner | $28M 3,000,000 shares | -20% | |
| 10Weak | PRVBsell Provention Bio, Inc. | Francisco Leon Chief Scientific Officer | $107k 10,674 shares | -1% | |
| 0Weak | PRVBsell Provention Bio, Inc. | Francisco Leon Chief Scientific Officer | $19k 1,943 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.